DENVER — A post hoc analysis of phase 3 pivotal data demonstrated sustained symptom improvements in patients with dry eye disease who received Xiidra, according to a presentation.
At the Association for Research in Vision and Ophthalmology meeting, John D. Sheppard, MD, MMSc, FACS, of Virginia Eye Consultants, told Healio that the analysis of data from the OPUS-2 and OPUS-3 studies allowed for the evaluation of populations that may have responded early, intermediately or later to treatment.
{{VIDEO}}
According to the abstract, 638 patients with a mean age of 58.4 years received Xiidra